GILD: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/6c6703ab-cd45-4521-8d38-259fda53d616/","filing_uuid":"6c6703ab-cd45-4521-8d38-259fda53d616","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/6c6703ab-cd45-4521-8d38-259fda53d616/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"DAVID J. SCHIAPPA","dt_posted":"2026-07-20T10:07:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"325 7th Street NW","registrant_address_2":"Suite 825","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":12675,"url":"https://lda.gov/api/v1/registrants/12675/","house_registrant_id":31811,"name":"THE DUBERSTEIN GROUP INC.","description":"Consulting","address_1":"325 7th Street NW","address_2":"Suite 825","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DAVID J. SCHIAPPA","contact_telephone":"+1 202-728-1100","dt_updated":"2026-07-24T11:16:57.603169-04:00"},"client":{"id":117738,"url":"https://lda.gov/api/v1/clients/117738/","client_id":1002537,"name":"GILEAD SCIENCES, INC.","general_description":"Biotechnology company that researches, develops and commercializes drugs.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-03-22"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to drug pricing Issues related to 340B program","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":79182,"prefix":null,"prefix_display":null,"first_name":"BENJAMIN","nickname":null,"middle_name":"R","last_name":"HOWARD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71388,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":"KATE","middle_name":"WINKLER","last_name":"KEATING","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}